Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis

Yuko Shimizu, Kazuo Fujihara, Sachiko Kubo, Toshiyuki Takahashi, Tatsuro Misu, Ichiro Nakashima, Kazumasa Yokoyama, Yasuto Itoyama, Shinichiro Uchiyama

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Optic neuritis and myelitis are manifestations in both multiple sclerosis (MS) and neuromyelitis optica (NMO). But unlike MS, NMO is characterized by severe optic neuritis, longitudinally extensive and transverse myelitis, and the presence of aquaporin-4 antibody. Since patients with optic neuritis and myelitis have often been diagnosed with "optic-spinal MS (OSMS)" in Asia, it was obscure whether "OSMS" is synonymous with NMO or includes both NMO and MS. Interferon β (IFNβ)-1a and -1b are used as the first-line disease-modifying therapy for MS. However, some neurologists have been reluctant to use IFNβ J to treat patients with optic-spinal symptoms, because IFNβ therapy is not efficacious in NMO. To evaluate the therapeutic effect of IFNβ in patients with ''genuine'' OSMS, we retrospectively evaluated Japanese MS patients who fulfilled the following six criteria: 1) Relapsing-remitting MS with optic-spinal presentation alone (no brain symptoms), 2) With or without asymptomatic brain MRI lesions, 3) Oligoclonal IgG band-positive, 4) aquaporin-4 antibody seronegativity, 5) No myelitis extending longitudinally over ≥ 3 vertebral segments, and 6) Duration of IFNβ-1b therapy ≥ 2 years. Among 157 patients with MS, six (four women and two men, age 43.8 ± 8.5 years old) met all the criteria. Their Expanded Disability Status Scale scores were lowered (4.1 ± 2.4 → 3.1 ± 2.8) (P = 0.033) and annualized relapse rate was decreased (0.59 ± 0.34 → 0.13 ± 0.15) (P = 0.027) after IFNβ-1b therapy. These results suggest that IFNβ is therapeutically effective in inhibiting functional worsening and reducing relapse rate in ''genuine'' OSMS.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalTohoku Journal of Experimental Medicine
Volume223
Issue number3
DOIs
Publication statusPublished - 2011 Mar 14

Keywords

  • Aquaporin-4 antibody
  • Interferon-beta therapy
  • Neuromyelitis optica
  • Oligoclonal IgG band
  • Optic-spinal multiple sclerosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis'. Together they form a unique fingerprint.

Cite this